Exicure Shares More Than Double After Nasdaq Listing Extension

Dow Jones09-19 06:30

By Josh Beckerman

Shares of Exicure surged in post-market trading after the company said it was granted a Nasdaq listing extension.

The stock rose 167% to $6.11 from its regular session close of $2.29. That left the shares down 21% this year.

The company said after the close it was granted an extension subject to showing compliance with all applicable listing criteria by Nov. 14. Shares rose 41% Monday after the company reported debt-for-equity exchange agreements with two promissory notes holders.

Exicure last week said it regained compliance with the $1 minimum bid price requirement after previously disclosing several Nasdaq deficiency notices.

In September 2022, the biotechnology company said it would suspend pre-clinical activities, halt all research and development, and would explore strategic alternatives to maximize stockholder value.

Write to Josh Beckerman at josh.beckerman@wsj.com

(END) Dow Jones Newswires

September 18, 2024 18:30 ET (22:30 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2468256639?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-19 06:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2468256639","market":"nz","top_or_hot":-1,"title":"Exicure Shares More Than Double After Nasdaq Listing Extension","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Josh Beckerman \n</p>\n<p>\n  Shares of Exicure surged in post-market trading after the company said it was granted a Nasdaq listing extension. \n</p>\n<p>\n  The stock rose 167% to $6.11 from its regular session close of $2.29. That left the shares down 21% this year. \n</p>\n<p>\n  The company said after the close it was granted an extension subject to showing compliance with all applicable listing criteria by Nov. 14. Shares rose 41% Monday after the company reported debt-for-equity exchange agreements with two promissory notes holders. \n</p>\n<p>\n  Exicure last week said it regained compliance with the $1 minimum bid price requirement after previously disclosing several Nasdaq deficiency notices. \n</p>\n<p>\n  In September 2022, the biotechnology company said it would suspend pre-clinical activities, halt all research and development, and would explore strategic alternatives to maximize stockholder value. \n</p>\n<p>\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  September 18, 2024 18:30 ET (22:30 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Exicure Shares More Than Double After Nasdaq Listing Extension</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nExicure Shares More Than Double After Nasdaq Listing Extension\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-19 06:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Josh Beckerman \n\n\n  Shares of Exicure surged in post-market trading after the company said it was granted a Nasdaq listing extension. \n\n\n  The stock rose 167% to $6.11 from its regular session ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"QLD","symbol_name":"纳指两倍做多ETF","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2468256639","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2468256639","pubTimestamp":1726698600,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Exicure surged in post-market trading after the company said it was granted a Nasdaq listing extension.The stock rose 167% to $6.11 from its regular session close of $2.29. That left the shares down 21% this year.The company said after the close it was granted an extension subject to showing compliance with all applicable listing criteria by Nov. 14. Shares rose 41% Monday after the company reported debt-for-equity exchange agreements with two promissory notes holders.Exicure last week said it regained compliance with the $1 minimum bid price requirement after previously disclosing several Nasdaq deficiency notices.In September 2022, the biotechnology company said it would suspend pre-clinical activities, halt all research and development, and would explore strategic alternatives to maximize stockholder value.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"QLD":"纳指两倍做多ETF","BK4585":"ETF&股票定投概念","PSQ":"纳指反向ETF","BK4139":"生物科技","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","NDAQ":"纳斯达克OMX交易所","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","XCUR":"Exicure, Inc.","BK4588":"碎股","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC",".IXIC":"NASDAQ Composite","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","QID":"纳指两倍做空ETF","BK4112":"金融交易所和数据","SQQQ":"纳指三倍做空ETF","TQQQ":"纳指三倍做多ETF"},"translate_title":"Exicure纳斯达克上市延期后股价上涨一倍多","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XCUR":1,"NQmain":1,"NDAQ":1,".IXIC":1,"TQQQ":0.6,"SQQQ":0.6,"QLD":0.6,"QID":0.6,"PSQ":0.6,"MNQmain":0.6},"content_text":"By Josh Beckerman \n\n\n  Shares of Exicure surged in post-market trading after the company said it was granted a Nasdaq listing extension. \n\n\n  The stock rose 167% to $6.11 from its regular session close of $2.29. That left the shares down 21% this year. \n\n\n  The company said after the close it was granted an extension subject to showing compliance with all applicable listing criteria by Nov. 14. Shares rose 41% Monday after the company reported debt-for-equity exchange agreements with two promissory notes holders. \n\n\n  Exicure last week said it regained compliance with the $1 minimum bid price requirement after previously disclosing several Nasdaq deficiency notices. \n\n\n  In September 2022, the biotechnology company said it would suspend pre-clinical activities, halt all research and development, and would explore strategic alternatives to maximize stockholder value. \n\n\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  September 18, 2024 18:30 ET (22:30 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.26.4","shortVersion":"4.26.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2468256639"}